Pacira BioSciences (PCRX) Projected to Post Quarterly Earnings on Thursday
Pacira BioSciences (PCRX) is expected to report its Q4 2025 earnings after market close on Thursday, February 26, 2026, with analysts projecting earnings of $0.85 per share and revenues of $201.93 million. Recent insider activity shows sales by CFO Shawn Cross and SVP Lauren Riker, totaling 30,416 shares sold in the last three months. The stock currently trades around $23, holds a "Hold" consensus rating from analysts, and has an average price target of $30.75.
Understanding Momentum Shifts in (PCRX)
This article analyzes Pacira Biosciences Inc. (PCRX), highlighting a mid-channel oscillation pattern and strong near-to-mid-term sentiment that could extend long-term. It provides three AI-generated trading strategies including position trading, momentum breakout, and risk hedging, with specific entry points, targets, and stop losses. The analysis also includes multi-timeframe signal analysis with support and resistance levels.
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit
Rosen Law Firm announces a class action lawsuit on behalf of purchasers of Pacira BioSciences, Inc. (NASDAQ: PCRX) securities between August 2, 2023, and August 8, 2024. Investors who purchased Pacira securities during this period may be entitled to compensation due to alleged false and misleading statements made by the company regarding its patent protections for the drug Exparel. The lawsuit claims that Pacira created a false impression of strong patent protections when they were, in fact, fragile, leading to investor damages.
Is Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Stock Price Struggling As A Result Of Its Mixed Financials?
Pacira BioSciences (NASDAQ:PCRX) has seen its share price decline by 8.6% over three months, despite its mixed financials. The company's low Return on Equity (ROE) of 2.9%, compared to an industry average of 22%, combined with a 61% net income decline over five years, suggests underlying issues with capital allocation or earnings retention. Although past performance is weak, analysts anticipate future earnings growth for Pacira BioSciences.
Pacira to Report 2025 Financial Results on Thursday February 26, 2026
Pacira BioSciences, Inc. announced it will report its fourth quarter and year-end financial results for 2025 after the U.S. markets close on Thursday, February 26, 2026. The company will host a live conference call and webcast at 4:30 p.m. ET to discuss the results, with pre-registration available for participants wishing to join the Q&A session. A replay of the webcast will be accessible on the Pacira website for two weeks following the call.
Pacira to Report 2025 Financial Results on Thursday February 26, 2026
Pacira BioSciences announced it will report its fourth quarter and full-year 2025 financial results after market close on Thursday, February 26, 2026. The company will host a live conference call and webcast at 4:30 p.m. ET to discuss the results, with replay availability on its website. Pacira is a leader in non-opioid pain therapies, offering commercial products like EXPAREL, ZILRETTA, and iovera, and has a clinical-stage pipeline.
Is Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Stock Price Struggling As A Result Of Its Mixed Financials?
Pacira BioSciences' stock price has been down 8.6% over the last three months, possibly due to mixed financials. The company's Return on Equity (ROE) is a low 2.9%, significantly below the industry average, which aligns with its 61% net income decline over five years. Despite retaining all its profits, there has been no earnings growth to show for it, though analysts predict future growth.
Pacira BioSciences Highlights Positive Impact of NOPAIN Act on Non-Opioid Pain Management in New Survey Findings
Pacira BioSciences, Inc. announced survey findings from the Voices for Non-Opioid Choices coalition indicating a positive early impact of the NOPAIN Act, which took effect in January 2025. The survey of nearly 750 healthcare facility representatives revealed high awareness of the legislation and a significant shift towards non-opioid pain management, leading to a decrease in opioid prescriptions post-surgery. Pacira's CEO and Voices' Executive Director expressed optimism about the Act's role in expanding access to non-opioid therapies and reducing opioid dependence for Medicare beneficiaries.
Pacira BioSciences, Inc. $PCRX Holdings Raised by Impax Asset Management Group plc
Impax Asset Management Group plc significantly increased its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 27.7% in the third quarter, now owning over 600,000 shares. Other institutional investors like Balyasny Asset Management and American Century Companies also boosted their holdings. Despite some insider selling, analysts maintain a "Hold" rating for PCRX with an average target price of $30.75, while the company focuses on its non-opioid pain management product, EXPAREL.
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Investors to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC has launched a securities investigation into Pacira BioSciences, Inc. (PCRX) concerning potential claims of corporate wrongdoing by the company and its officers/directors. Investors who acquired Pacira securities before August 2, 2023, and still hold them, are encouraged to contact the firm to assist with the investigation. The firm operates on a contingency fee basis, meaning there is no cost to investors unless they are successful.
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences announced inducement grants to 14 new employees on February 3, 2026, as per Nasdaq Listing Rule 5635(c)(4). These awards, consisting of stock options and restricted stock units, were approved by the People & Compensation Committee without stockholder approval to incentivize new hires. The awards have vesting schedules dependent on continued employment, with specific exercise prices for stock options and annual vesting for restricted stock units.
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences announced the granting of inducement awards to 14 new employees on February 3, 2026, under its Amended and Restated 2014 Inducement Plan. These awards, authorized by the Board of Directors' People & Compensation Committee without stockholder approval, include stock options for 58,000 shares and restricted stock units for 41,300 shares of Pacira common stock. The grants serve as a material inducement for their employment, with vesting schedules tied to continued employment.
Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Pacira Biosciences announced inducement grants issued under Nasdaq Listing Rule 5635(C)(4). The grants are typically provided to new employees as a material inducement to accept employment. This brief report, sourced from Refinitiv and Reuters, indicates standard corporate governance and compliance with Nasdaq regulations.
Pacira BioSciences reports inducement grants under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences has reported making inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). The company, listed under the ticker PCRX, specializes in non-opioid pain management treatments like EXPAREL, ZILRETTA, and Iovera. This announcement comes amidst other recent news, including previous reports of inducement grants and new board appointments.
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences announced inducement awards granted on February 3, 2026, to 14 new employees under its 2014 Inducement Plan. These awards, consisting of stock options and restricted stock units, were approved by the People & Compensation Committee without stockholder approval, in accordance with Nasdaq Listing Rule 5635(c)(4). The grants serve as a material inducement for their employment, with vesting contingent on continued employment.
Pacira hands new hires $21.02 stock options and RSUs
Pacira BioSciences (Nasdaq: PCRX) granted inducement equity awards to 14 new employees on February 3, 2026, under its Amended and Restated 2014 Inducement Plan. Four employees received stock options for 58,000 shares with a $21.02 exercise price, vesting over four years, while 14 employees received restricted stock units for 41,300 shares, vesting annually over four years starting February 1, 2027. These awards, totaling 99,300 shares, were approved by the People & Compensation Committee without stockholder approval, consistent with Nasdaq Listing Rule 5635(c)(4), to incentivize new talent.
Pacira BioSciences officer Williams sells $269k in shares
Kristen Williams, Chief Administrative Officer of Pacira BioSciences, recently sold shares totaling over $269,000, primarily to cover tax obligations from vested restricted stock units. Following these transactions, Williams directly owns 131,303 shares. This comes amidst other company developments, including record revenues for 2025, new distribution agreements, and a board appointment.
Pacira BioSciences officer Williams sells $269k in shares By Investing.com
Kristen Williams, Chief Administrative Officer of Pacira BioSciences, recently sold 13,137 shares for approximately $269,702 and 17,134 shares for $351,932 to cover tax withholding obligations. These transactions were executed under a Rule 10b5-1 trading plan, leaving Williams with 131,303 directly owned shares. The company has also reported strong 2025 revenues, strategic partnerships, new board appointments, and positive clinical study results for its iovera° treatment.
Pacira BioSciences SVP Lauren Riker sells $83k in stock
Lauren Riker, SVP of Finance at Pacira BioSciences, sold 4,000 shares for $83,240 and disposed of 2,751 shares for $56,505 to cover tax obligations. Despite the insider selling, Pacira maintains a strong Piotroski Score and management is actively buying back shares, with an earnings report scheduled for February 19. The company also reported record revenues for 2025 due to strong EXPAREL performance and is expanding its reach through new distribution agreements.
Pacira BioSciences SVP Lauren Riker sells $83k in stock By Investing.com
Lauren Riker, SVP of Finance at Pacira BioSciences, sold 4,000 shares of common stock for approximately $83,240 and disposed of an additional 2,751 shares to cover tax withholding obligations. Despite this insider selling, InvestingPro data indicates that Pacira (NASDAQ: PCRX) maintains a strong Piotroski Score of 9 and management is actively engaging in share buybacks. The company, which is preparing for its earnings report on February 19, has also reported record revenues for 2025 due to strong EXPAREL sales and expanded its board of directors.
Pacira BioSciences officer Williams sells $269k in shares
Kristen Williams, Chief Administrative Officer of Pacira BioSciences, sold 13,137 shares of common stock for approximately $269,702 on February 2, 2026, and an additional 17,134 shares on January 30, 2026, valued at $351,932, to cover tax obligations. Following these transactions, Williams directly owns 131,303 shares. These sales were executed under a Rule 10b5-1 trading plan.
Pacira BioSciences (NASDAQ:PCRX) SVP Lauren Riker Sells 4,000 Shares
Pacira BioSciences (NASDAQ:PCRX) SVP Lauren Riker sold 4,000 shares of the company's stock on February 2nd at an average price of $20.81, for a total value of $83,240. This transaction reduced her stake by 7.1% to 52,313 shares. The company's stock was trading down 0.9% mid-day, and analysts currently hold a consensus "Hold" rating with an average target price of $30.75.
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates
The article identifies five drug/biotech companies—Zoetis (ZTS), Pacira BioSciences (PCRX), Apellis Pharmaceuticals (APLS), Acadia Pharmaceuticals (ACAD), and Denali Therapeutics (DNLI)—that are expected to exceed fourth-quarter earnings estimates. These predictions are based on a proprietary Earnings ESP methodology combined with Zacks Ranks, which historically indicates a high chance of an earnings surprise. The companies' upcoming results are anticipated to be driven by strong product sales and pipeline developments.
Great Lakes Advisors LLC Decreases Stake in Pacira BioSciences, Inc. $PCRX
Great Lakes Advisors LLC significantly reduced its stake in Pacira BioSciences (NASDAQ:PCRX) by 51.3% in Q3, now owning 105,743 shares valued at approximately $2.73 million. Insider selling has also been noted, with key executives offloading shares worth over $850,000 in the last 90 days. Despite a consensus "Hold" rating from Wall Street with a $30.75 price target, the company's stock shows some institutional buying interest from other funds.
Gagnon Securities LLC Grows Stock Holdings in Pacira BioSciences, Inc. $PCRX
Gagnon Securities LLC increased its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 22.1% in Q3, bringing its total to 449,717 shares valued at $11.59 million, making it the 17th largest holding in their portfolio. Despite institutional investors owning 99.73% of the stock, recent insider selling totaled 34,336 shares. Analysts currently have a "Hold" consensus rating on PCRX, with an average price target of $30.75, while the stock trades near $20.09 with a market cap of approximately $864 million.
Pacira BioSciences, Inc. (NASDAQ:PCRX) Given Consensus Recommendation of "Hold" by Analysts
MarketBeat reports that six analysts have given Pacira BioSciences, Inc. (NASDAQ:PCRX) a consensus "Hold" rating, with an average one-year price objective of $30.75. The company recently reported Q4 earnings per share of $0.70, beating estimates, while revenue slightly missed expectations. Insider selling has occurred recently, with executives selling 34,336 shares in the past 90 days.
Pacira BioSciences appoints Samit Hirawat to board of directors By Investing.com
Pacira BioSciences, Inc. has appointed Samit Hirawat, M.D., formerly of Bristol Myers Squibb and Novartis Pharmaceuticals, to its Board of Directors, expanding it to 10 members. This appointment comes as Pacira, trading near its 52-week low, continues to advance its non-opioid pain therapies and reports strong financial performance for 2025. The company also faces a patent infringement lawsuit and a push for an immediate sale by an investment firm.
Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors
Pacira BioSciences has appointed Dr. Samit Hirawat to its Board of Directors, increasing the board to 10 members. Dr. Hirawat brings over 25 years of clinical development and industry expertise, having previously served as Chief Medical Officer at Bristol Myers Squibb and Head of Oncology Development at Novartis. His appointment is expected to bolster Pacira's mission to advance innovative non-opioid pain therapies.
Pacira BioSciences appoints Samit Hirawat to board of directors
Pacira BioSciences has appointed Samit Hirawat, M.D., formerly of Bristol Myers Squibb and Novartis Pharmaceuticals, to its Board of Directors, expanding the board to 10 members. Dr. Hirawat brings extensive biopharmaceutical leadership experience, having overseen global drug development and advanced multiple therapies. This appointment comes as Pacira, trading near its 52-week low but with strong fundamentals, continues to focus on non-opioid pain therapies and advance its pipeline.
Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors
Pacira BioSciences has appointed Samit Hirawat, M.D., to its Board of Directors, increasing the board to 10 members. Dr. Hirawat brings over 25 years of clinical development and industry expertise, having previously served as Chief Medical Officer at Bristol Myers Squibb and in leadership roles at Novartis. His appointment is expected to strengthen Pacira's mission to advance non-opioid pain therapies.
Will Pacira (PCRX) Beat Estimates Again in Its Next Earnings Report?
Pacira (PCRX) is predicted to beat its upcoming earnings estimates based on its strong historical performance and positive Zacks Earnings ESP of +7.38%. The company has consistently topped earnings expectations, with an average surprise of 5.24% over the past two quarters. Combined with a Zacks Rank #2 (Buy), this suggests a high probability of another positive earnings surprise for investors.
Discipline and Rules-Based Execution in PCRX Response
This article provides an in-depth analysis of Pacira Biosciences Inc. (NASDAQ: PCRX), highlighting weak near and mid-term sentiment, but a neutral long-term outlook. It identifies an exceptional risk-reward setup, targeting a 14.0% gain versus a 0.3% risk, and outlines institutional trading strategies based on AI models for various risk profiles. The analysis also includes multi-timeframe signal analysis with support and resistance levels.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into Pacira BioSciences, Inc. (NASDAQ:PCRX) for potential corporate wrongdoing by its officers and/or directors. The law firm is encouraging investors who purchased Pacira securities before August 2, 2023, and still hold them, to learn more and assist with the investigation. The firm specializes in securities fraud class actions and shareholder derivative suits, representing investors on a contingency fee basis.
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pacira BioSciences, Inc. (NASDAQ: PCRX) securities. The investigation concerns whether Pacira and its officers/directors engaged in corporate wrongdoing. Shareholders who purchased Pacira securities before August 2, 2023, and still hold them, are encouraged to contact the firm to assist with the investigation.
Pacira partners with LG Chem to make EXPAREL® available in select APAC markets
Pacira BioSciences has formed a partnership with LG Chem to commercialize its long-acting pain medication, EXPAREL, in key Asia-Pacific markets. LG Chem will have exclusive rights to distribute EXPAREL for postsurgical pain management, leveraging its expertise in orthopedic and surgical markets. This collaboration aims to provide enhanced opioid-sparing pain control to a region with significant unmet needs, with LG Chem also responsible for securing regulatory approvals.
DOMA Perpetual Capital to offer nominees for Pacira BioSciences board
The article states that DOMA Perpetual Capital plans to nominate candidates for the board of directors of Pacira BioSciences. No further details about the reasons or implications of this move are provided in this brief snippet.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Pacira BioSciences, Inc. (NASDAQ:PCRX). The firm is encouraging investors who purchased Pacira securities prior to August 2, 2023, and still hold them, to come forward and assist with the investigation. This class action aims to recover investor capital and ensure corporate accountability.
Revenues Working Against Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Share Price Following 28% Dive
Pacira BioSciences' share price recently dropped 28%, resulting in a 14% decrease over the last year. The company's low price-to-sales (P/S) ratio of 1.1x, significantly below the industry average, is attributed to its sluggish revenue growth compared to competitors. Analyst forecasts predict an 8.4% annual revenue growth for Pacira BioSciences over the next three years, well below the industry's projected 33%, leading investors to pay a reduced amount for the stock due to limited future growth expectations.
Do Options Traders Know Something About Pacira BioSciences Stock We Don't?
The article discusses the high implied volatility of Pacira BioSciences (PCRX) options, specifically the Jan. 16, 2026 $12.50 Call, suggesting that options traders might be anticipating a significant price movement. Despite the potential for a big move, analysts currently rate PCRX as a Zacks Rank #3 (Hold), although earnings estimates for the current quarter have seen an increase. This situation could present an opportunity for experienced options traders to sell premium, betting that the stock's movement will be less than what the high implied volatility suggests.
Pacira BioSciences Inc (PCRX) Stock Price Down 5.4% on Jan 16
Shares of Pacira BioSciences Inc (PCRX) fell 5.40% on January 16, closing at $19.54, which is 29.32% below its 52-week high. Despite the dip, analyst forecasts suggest a potential upside, with an average target price of $33.00, implying a 68.93% increase from the current price. GuruFocus estimates the fair value at $36.86, indicating an 88.69% upside.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pacira BioSciences, Inc. (NASDAQ:PCRX) securities who bought prior to August 2, 2023, and continue to hold them. The investigation focuses on whether Pacira and its officers engaged in corporate wrongdoing. Stockholders are encouraged to contact the law firm for more information and to assist in the investigation.
PCRX, LG Chem Partner to Expand Exparel Reach Across the Asia-Pacific
Pacira BioSciences (PCRX) has partnered with LG Chem to expand the reach of its opioid-sparing postsurgical pain management drug, Exparel, across select Asia-Pacific markets. LG Chem will gain exclusive commercialization rights in the region, handling regulatory filings and sales, while Pacira will manufacture the drug and receive upfront payments and royalties. This collaboration aims to leverage LG Chem's regional expertise to tap into a large surgical patient base and generate new revenue streams for Pacira, especially as its recent Q4 revenues fell below market expectations.
PCRX, LG Chem Partner to Expand Exparel Reach Across the Asia-Pacific
Pacira BioSciences (PCRX) has partnered with LG Chem to expand the availability of its opioid-sparing postsurgical pain management drug, Exparel, across select Asia-Pacific markets. LG Chem will gain exclusive commercialization rights for Exparel in the region, handling regulatory filings and aiming to submit marketing authorization applications in South Korea and Thailand within six months. This collaboration is expected to accelerate Exparel's international adoption, leverage LG Chem's regional expertise, and contribute to Pacira BioSciences' long-term growth and revenue momentum following recent financial performance below market expectations.
Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets
Pacira BioSciences, Inc. has partnered with LG Chem to commercialize EXPAREL® in select Asian-Pacific markets, aiming to expand access to opioid-sparing postsurgical pain management. LG Chem will be the exclusive distributor, responsible for securing regulatory approvals and plans to file for marketing authorizations in South Korea and Thailand within six months. This collaboration supports Pacira's 5x30 strategy and leverages LG Chem's expertise in orthopedic and surgical markets.
LG Chem to distribute Pacira’s EXPAREL in Asian-Pacific markets
Pacira BioSciences, Inc. has signed an exclusive distribution agreement with LG Chem for its non-opioid pain management product, EXPAREL, in key Asian-Pacific markets. LG Chem will be responsible for commercialization and regulatory approvals, starting with South Korea and Thailand. This partnership aligns with Pacira's strategy to expand global access to opioid-sparing pain management solutions.
Pacira BioSciences Signs Deal With LG Chem To Commercialize EXPAREL In Select Asia-Pacific Markets
Pacira BioSciences has signed an exclusive agreement with LG Chem to commercialize EXPAREL in select Asia-Pacific markets, aiming to expand access to opioid-sparing postsurgical pain control. Pacira will receive an upfront payment, transfer price, and tiered royalties. LG Chem plans to seek marketing authorizations in South Korea and Thailand within six months.
Opioid-sparing EXPAREL to reach patients in South Korea and Thailand
Pacira BioSciences, Inc. announced an exclusive agreement with LG Chem to commercialize its opioid-sparing pain therapy, EXPAREL, in select Asia-Pacific markets. LG Chem plans to file for regulatory approvals in South Korea and Thailand within six months, aiming to address the unmet need for long-acting postsurgical pain control in the region. This partnership advances Pacira's 5x30 strategy to expand global access to non-opioid pain solutions.
Assessing Pacira BioSciences (PCRX) Valuation After Record EXPAREL Quarter Buybacks And Activist Pressure
Pacira BioSciences (PCRX) recently reported record EXPAREL sales and completed a share repurchase program, yet its short-term stock performance has declined. The company is considered undervalued by some analysts at $29, primarily due to improved gross margins and projected earnings growth from manufacturing efficiencies. However, its current P/E ratio is significantly higher than the industry average, raising questions about potential mispricing or execution risks.
Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets
Pacira BioSciences has partnered with LG Chem to expand access to its non-opioid pain therapy, EXPAREL, in select Asian-Pacific markets. LG Chem will have exclusive commercialization rights for EXPAREL in the region, focusing on orthopedic and surgical markets where there is a significant unmet need for long-acting postsurgical pain control. Pacira will receive an upfront payment, transfer price, and tiered royalties, while LG Chem will handle regulatory approvals and plans to file for marketing authorizations in South Korea and Thailand within six months.
Pacira Stock (-9.6%): EXPAREL Decel Spooks the Street
This article discusses the negative market reaction to Pacira BioSciences stock, which dropped 9.6%, due to a deceleration in sales of its drug EXPAREL. The stock decline indicates investor concern over the drug's performance. The original content provided is very minimal and mostly consists of website navigation elements.
